The Globe and Mail reports in its Tuesday, Sept. 24, edition that Canaccord Genuity analyst Tania Armstrong-Whitworth commenced coverage of Vancouver-based Satellos Bioscience with a "speculative buy" recommendation and a share target of $1. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $1.10. Ms. Armstrong-Whitworth says in a note: "Satellos Bioscience's lead drug candidate, SAT-3247, is initially being developed for the treatment of Duchenne Muscular Dystrophy (DMD). Today, DMD remains incurable. Standard of care treatments only manage symptoms and slow disease progression. In preclinical animal studies, SAT-3247 demonstrated the ability to regenerate skeletal muscle lost in DMD. In September, 2024, Satellos Bioscience initiated its first in-human study, a Phase 1 trial in healthy volunteers assessing safety. It plans to conduct two Phase 1 studies in DMD patients in 2025, before beginning a Phase 2 proof-of-concept trial later in the year. It is fully funded to execute its clinical development plan through the end of 2025. We believe the stock will move in response to data readouts from these trials."